Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)
This is a Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, multicenter study investigating the safety, tolerability and efficacy of two oral doses of GS-9450 in adults with chronic Hepatitis C Virus (HCV). Approximately 240 subjects 18-65 years of age who meet study entry criteria will be randomized (in other words, selected at random, like flipping a coin) to one of three treatment groups (80 subjects per treatment group) as follows:GS-9450 10 mg once daily,GS-9450 40 mg once daily, or matching placebo once daily.
Following randomization, subjects will return within seven business days for a Baseline (Day 1) visit, at which time study medication will be dispensed and subjects will enter a 26 week treatment phase. During the treatment phase, subjects will receive study drug once daily for 24 weeks and then taper off of study drug over the following 2 weeks by receiving study drug once every other day for one week and then every 3 days for one week. Following completion of the treatment phase, subjects will enter a 4-week off-treatment follow-up phase.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大
-
-
Ontario
-
London、Ontario、加拿大
-
-
-
-
-
Berlin、德国
-
Bonn、德国
-
Essen、德国
-
Frankfurt am Main、德国
-
Hamburg、德国
-
Hannover、德国
-
Köln、德国
-
Mainz、德国
-
-
-
-
-
Bialystok、波兰
-
Bydgoszcz、波兰
-
Chorzów、波兰
-
Kielce、波兰
-
Wroclaw、波兰
-
-
-
-
-
San Juan、波多黎各
-
Santurce、波多黎各
-
-
-
-
Arizona
-
Phoenix、Arizona、美国
-
Tucson、Arizona、美国
-
-
California
-
Anaheim、California、美国
-
Beverly Hills、California、美国
-
Cypress、California、美国
-
La Jolla、California、美国
-
Mission Hills、California、美国
-
Palm Springs、California、美国
-
Pasadena、California、美国
-
San Clemente、California、美国
-
San Diego、California、美国
-
-
District of Columbia
-
Washington、District of Columbia、美国
-
-
Florida
-
Hialeah、Florida、美国
-
Miami、Florida、美国
-
North Miami Beach、Florida、美国
-
Orlando、Florida、美国
-
Sarasota、Florida、美国
-
Tampa、Florida、美国
-
-
Georgia
-
Decatur、Georgia、美国
-
-
Illinois
-
Chicago、Illinois、美国
-
-
Indiana
-
Indianapolis、Indiana、美国
-
-
Kentucky
-
Louisville、Kentucky、美国
-
-
Louisiana
-
Baton Rouge、Louisiana、美国
-
New Orleans、Louisiana、美国
-
-
Maryland
-
Annapolis、Maryland、美国
-
Baltimore、Maryland、美国
-
-
Massachusetts
-
Boston、Massachusetts、美国
-
-
Michigan
-
Novi、Michigan、美国
-
St. Louis、Michigan、美国
-
-
Minnesota
-
Plymouth、Minnesota、美国
-
-
Nebraska
-
Omaha、Nebraska、美国
-
-
Nevada
-
Las Vegas、Nevada、美国
-
-
New Jersey
-
Hillsborough、New Jersey、美国
-
Morristown、New Jersey、美国
-
-
New Mexico
-
Santa Fe、New Mexico、美国
-
-
New York
-
Johnson City、New York、美国
-
New York、New York、美国
-
Plainview、New York、美国
-
-
Ohio
-
Cincinnati、Ohio、美国
-
Cleveland、Ohio、美国
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国
-
-
Rhode Island
-
Providence、Rhode Island、美国
-
-
Tennessee
-
Chattanooga、Tennessee、美国
-
Germantown、Tennessee、美国
-
-
Texas
-
Dallas、Texas、美国
-
San Antonio、Texas、美国
-
-
Virginia
-
Fairfax、Virginia、美国
-
Falls Church、Virginia、美国
-
Norfolk、Virginia、美国
-
-
Washington
-
Seattle、Washington、美国
-
-
Wisconsin
-
Madison、Wisconsin、美国
-
-
-
-
-
Brighton、英国
-
London、英国
-
Nottingham、英国
-
Sheffield、英国
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adult subjects, ages 18-65
- Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening
- Screening Knodell necroinflammatory score >= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period
- ALT > the upper limit of the normal range (ULN) but < 10 X ULN at the screening visit
- Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy
- BMI between 19 and 36 kg/m2 (inclusive)
- Creatinine clearance >= 70 mL/min
- absolute neutrophil count >= 1000/mm3
- Hemoglobin > 10 g/dL
- Have no clinical or laboratory evidence of hepatic decompensation
Exclusion Criteria:
- Decompensated liver disease
- Child-Pugh grade B or C cirrhosis
- Evidence of hepatocellular carcinoma
- Positive urine drug screen for cocaine or amphetamines
- Infection with HCV genotype 3
- Co-infection with hepatitis B virus or human immunodeficiency virus
- Pancreatitis
- Recent significant infection or symptoms of infection
- Autoimmune disorders
- Any history of seizure
- Is a public transportation operator (pilot of airplane or ship; air traffic controller; bus, train or subway driver) or operates heavy construction machinery
- Transplantation
- History of malignancy
- Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males
- History of or current binge drinking
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:GS-9450 10 mg/day
GS-9450 taken as one 10 mg capsule by mouth once daily
|
Taken as one capsule by mouth once daily
|
实验性的:GS-9450 40 mg/day
GS-9450 taken as one 40 mg capsule by mouth once daily
|
Taken as one capsule by mouth once daily
|
安慰剂比较:Placebo
Placebo taken as one placebo capsule by mouth once daily
|
Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Histologic response, defined as a >= 2-point decrease in Knodell necroinflammatory score with no concurrent worsening in the Knodell fibrosis score, at Week 24 .
大体时间:Week 24 on-treatment
|
Week 24 on-treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change (absolute, percent) from baseline in the Knodell necroinflammatory score
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change (absolute, percent) from pretreatment in alanine aminotransferase (ALT) levels
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities
大体时间:Up to 24 weeks plus 30 days following the last dose of study drug
|
Up to 24 weeks plus 30 days following the last dose of study drug
|
|
Change (absolute, percent) from baseline in cytokeratin-18 caspase cleavage fragment levels
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from baseline in hepatic collagen staining area as measured by morphometry of liver biopsy specimens
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from baseline in the percent of apoptotic cells
大体时间:Baseline to Week 24
|
Change from baseline in the percent of apoptotic cells (transferase deoxyuridine triphosphate [dUTP] nick end labeling [TUNEL] positive) as measured by TUNEL staining of liver biopsy specimens
|
Baseline to Week 24
|
Change from baseline in percent of anti-M30 monoclonal antibody-positive hepatocytes
大体时间:Baseline to Week 24
|
Change from baseline in percent of anti-M30 monoclonal antibody-positive hepatocytes (for cytokeratin-18 neoantigen expression) as measured by immunohistochemical staining of liver biopsy specimens
|
Baseline to Week 24
|
Change From Baseline in HCV RNA
大体时间:Baseline to to Week 24
|
Baseline to to Week 24
|
合作者和调查者
调查人员
- 研究主任:Ken Hirsch, MD、Gilead Sciences
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
丙肝病毒感染的临床试验
-
Assistance Publique Hopitaux De Marseille未知
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases (NIAID)完全的
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health and Health Disparities...完全的
-
National Taiwan University Hospital未知
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos III完全的
GS-9450的临床试验
-
Gilead Sciences完全的丙型肝炎病毒感染美国, 法国, 英国, 德国, 加拿大, 澳大利亚, 新西兰, 波多黎各
-
Gilead Sciences完全的丙型肝炎病毒感染美国, 法国, 英国, 德国, 澳大利亚, 加拿大, 新西兰, 波多黎各
-
Gesynta Pharma ABCTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB完全的
-
Gilead Sciences完全的丙型肝炎美国, 法国, 英国, 德国, 加拿大, 澳大利亚, 新西兰, 波多黎各